Kalaris Therapeutics Statistics
Total Valuation
KLRS has a market cap or net worth of $56.18 million. The enterprise value is -$35.96 million.
| Market Cap | 56.18M |
| Enterprise Value | -35.96M |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, before market open.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KLRS has 23.80 million shares outstanding. The number of shares has increased by 235.77% in one year.
| Current Share Class | 23.80M |
| Shares Outstanding | 23.80M |
| Shares Change (YoY) | +235.77% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 6.02% |
| Owned by Institutions (%) | 16.19% |
| Float | 7.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.97 |
| P/TBV Ratio | 0.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.98, with a Debt / Equity ratio of 0.02.
| Current Ratio | 10.98 |
| Quick Ratio | 10.70 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.91% and return on invested capital (ROIC) is -53.22%.
| Return on Equity (ROE) | -79.91% |
| Return on Assets (ROA) | -31.03% |
| Return on Invested Capital (ROIC) | -53.22% |
| Return on Capital Employed (ROCE) | -52.60% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.21M |
| Employee Count | 20 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -64.19% |
| 50-Day Moving Average | 3.55 |
| 200-Day Moving Average | 5.92 |
| Relative Strength Index (RSI) | 20.49 |
| Average Volume (20 Days) | 84,499 |
Short Selling Information
The latest short interest is 318,361, so 1.34% of the outstanding shares have been sold short.
| Short Interest | 318,361 |
| Short Previous Month | 345,990 |
| Short % of Shares Out | 1.34% |
| Short % of Float | 4.39% |
| Short Ratio (days to cover) | 5.55 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.76M |
| Pretax Income | -44.26M |
| Net Income | -44.26M |
| EBITDA | n/a |
| EBIT | -47.76M |
| Earnings Per Share (EPS) | -$2.06 |
Balance Sheet
The company has $93.54 million in cash and $1.40 million in debt, with a net cash position of $92.14 million or $3.87 per share.
| Cash & Cash Equivalents | 93.54M |
| Total Debt | 1.40M |
| Net Cash | 92.14M |
| Net Cash Per Share | $3.87 |
| Equity (Book Value) | 57.67M |
| Book Value Per Share | 2.42 |
| Working Capital | 87.18M |
Cash Flow
In the last 12 months, operating cash flow was -$41.02 million and capital expenditures -$200,000, giving a free cash flow of -$41.22 million.
| Operating Cash Flow | -41.02M |
| Capital Expenditures | -200,000 |
| Depreciation & Amortization | 33,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -41.22M |
| FCF Per Share | -$1.73 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KLRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -235.77% |
| Shareholder Yield | -235.77% |
| Earnings Yield | -78.79% |
| FCF Yield | -73.37% |
Analyst Forecast
The average price target for KLRS is $18.71, which is 692.80% higher than the current price. The consensus rating is "Buy".
| Price Target | $18.71 |
| Price Target Difference | 692.80% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |